Merck & Co.
AWARDS
NEWS
Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC).
Ken Frazier, Merck’s chief executive officer, is reminding the world that vaccine development takes time, typically a decade, and hoping for a viable vaccine against the novel coronavirus by the end of December is premature.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
JOBS
IN THE PRESS